Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

NO_LONGER_AVAILABLE

Conditions studied: Cancers With NTRK, ROS1, or ALK Gene Fusions

In brief

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Key facts

Study ID

NCT03066661

Run by

Hoffmann-La Roche

Last updated by the study team

2019-04-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
• Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
• Willing and able to provide written, signed informed consent
• Medically suitable for treatment with entrectinib (RXDX-101)

You may not qualify if…

• Currently enrolled in an ongoing clinical study with any other investigational agent

Where it is running

• 1-844-Startrk (782-7875) — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.